fda approv olumi
friday fda announc approv olumi rheumatoid
arthriti patient inadequ respons one tnf antagonist
label includ black box warn thrombosi expect
requir inadequ respons increment neg
reflect modestli lower penetr estim maintain buy
rate pt
fda approv olumi black prior tnf requir
friday fda announc approv olumi treatment
rheumatoid arthriti ra inadequ respons one
tnf antagonist therapi notabl dose dose
approv expect remind adcom vote favor
dose april see note http //
vote mention requir inadequ
respons tnf believ approv patient respond
tnf increment neg given applic includ
restrict entir surpris given adcom commentari
april suggest drug may use later line therapi
approv label show black box warn sever
side effect typic jak inhibitor ra infect malign
also thrombosi label jak inhibitor
xeljanz label includ inadequ respons tnf
increment neg alreadi reduc penetr expect
base adcom commentari believ approv remov
overhang stock addit entitl mileston
payment first us approv page
rais likelihood approv olumi
trim penetr rate maintain pt olumi
repres pt us row
model chang increas likelihood approv olumi
 trim penetr rate
maintain pt adjust non-gaap ep align
detail break-out given compani ex-stock option ex-mileston
ex-acquisit relat cost ex-financi one timer varianc tabl
detail
catalyst focu molecul pivot phase
trial result jakafi steroid refractori agvhd capmatinib c-
phase data nsclc initi phase data
cholangiocarcinoma
tr target
valuat risk dcf/npv valuat use probabl adjust peak sale
discount rate probabl success yield pt jakafi
mf pv gvhd olumi epacadostat melanoma
solid tumor iclusig cash/technolog bull/bear case model yield
pt risk includ failur epacadostat competit impact jakafi olumi uptak
page
data catalyst next month highlight
page
candidatetargettim mileston settingpartnerepacadostat durvalumab data solid tumorsio data pair biopsi trial multipl tumor datasolid datasolid tumorsruxolitnib phase resultssteroid refrectori initi pivot programpsoriat arthritis phase glioblastoma liver cancer incyt corpor
page
 epacadostat- jakavi olumiant- olumi mileston number factset managementvaluationfromtochangediscount adjust sale probabl success weight weight epacadostat- technolog incyt corpor
page
page
quarterli sale iclusig cml- product olumi ra us- ra row- fair valu acquisit incom incom non-gaap inc net incom non-gaap ex incom share outstand corpor
page
annual jakafi gvhd/transplant- iclusig cml- total product total fair valu acquisit incom interest incom non-gaap ex incom share outstand corpor
commerci stage biotech compani believ gener signific cash flow
two partner asset develop deep pipelin oncolog asset incyt commerci asset jakafi
could see upsid addit indic fulli partner arthriti molecul olumi
launch would help fund well posit immuno-oncolog target molecul
jakafi above-p biotech growth addit upsid new indic jakafi rapidli
grow drug myelofibrosi polycythemia vera project revenu
jakafi drug show durabl effect clinic benefit importantli jakafi
also shown encourag clinic benefit graft vs host diseas project peak
sale additoin valu come baricitinib non-oncolog rheumatoid arthriti ra focus cash
valuat risk
dcf/npv valuat use probabl adjust peak sale discount rate
probabl success yield pt jakafi mf pv gvhd
olumi epacadostat melanoma solid tumor iclusig
cash/technolog bull/bear case model yield pt risk includ failur
epacadostat competit impact jakafi olumi uptak
compani mention note
peter lawson herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
